NCT06077669

Multimodal Brain Imaging of Methylphenidate in Children and Adolescents With ADHD

Multimodal Brain Imaging of the Neural Effects of Methylphenidate in Children and Adolescents With ADHD

• Status: Withdrawn
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Johns Hopkins University · Academic / Other
• Sex: All
• Age: 6 Years – 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this proposal is to develop brain imaging tools to measure the effects of methylphenidate in children and adolescents with attention deficit hyperactivity disorder (ADHD). Methylphenidate is an FDA-approved treatment for ADHD. Specifically, the investigators will correlate brain activity during cognitive tasks and brain chemistry with cognitive performance. These measures could help the investigators understand how current ADHD medications work and then could be used to develop novel drugs to treat ADHD in children and adolescents.

Conditions

• ADHD

Interventions

Type	Name	Description
DRUG	Methylphenidate	Single oral dose of methylphenidate (5mg or 10 mg)
DRUG	Placebo	oral placebo

Timeline

• Start date: 2024-04-16
• Primary completion: 2028-12-01
• Completion: 2029-01-01
• First posted: 2023-10-11
• Last updated: 2024-03-15

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study